Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Implications of Aberrant Retinoblastoma Signaling in Patients With Grade 4 IDH-Mutant Astrocytoma: A Retrospective Cohort Study.

Neurology - 27 Jan 2026

Maqbool Muhammad Asad, Jenkins Robert B, Ida Cristiane M, Burns Terry C, Drucker Kristen L, Kollmeyer Thomas M, Lachance Daniel H, Raghunathan Aditya, Vaubel Rachael A, Giannini Caterina, Decker Paul A, Eckel-Passow Jeanette E, Kizilbash Sani H

Abstract excerpt

BACKGROUND AND OBJECTIVES: The data on the prognostic factors of grade 4 isocitrate dehydrogenase (IDH)-mutant astrocytoma remain limited since the 2021 update of the World Health Organization classification of CNS tumors. This study aimed to investigate prognostic factors affecting survival in grade 4 IDH-mutant astrocytoma. METHODS: In this retrospective cohort study, medical records of patients diagnosed with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p16

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Isocitrate Dehydrogenase

Share to Neoplasm Grading

Share to Progression-Free Survival

Source

Identifiers

PMID: 41418095
DOI: 10.1212/WNL.0000000000214478

Genes

CDKN2A
MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Implications of Aberrant Retinoblastoma Signaling in Patients With Grade 4 IDH-Mutant Astrocytoma: A Retrospective Cohort Study.PMID 41418095Read ↗

An Analysis for IDH-Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice.Semantic proximity Read ↗

Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4.Semantic proximity Read ↗

Expanding the molecular grading criteria in IDH-mutant astrocytoma.Semantic proximity Read ↗

Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors.Semantic proximity Read ↗

Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study.Semantic proximity Read ↗

A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design.Semantic proximity Read ↗

Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study.Semantic proximity Read ↗

Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.Semantic proximity Read ↗

Molecular and clinical prognostic factors in isocitrate dehydrogenase-mutant astrocytomas: Insights into biomarker-driven stratification.Semantic proximity Read ↗

A comprehensive clinical, molecular, radiological, and surgical analysis for predicting prognosis in isocitrate dehydrogenase-mutant astrocytoma patients.Semantic proximity Read ↗

Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.Semantic proximity Read ↗

MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.